Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments in systemic immunomodulatory therapy for psoriasis.

Emily M Berger1, Alice B Gottlieb

  • 1Department of Dermatology, Tufts-New England Medical Center, Tufts University School of Medicine, Tufts-NEMC Box #114, 750 Washington Street, Boston, MA 02111, United States. emily.berger@tufts.edu

Current Opinion in Pharmacology
|July 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study.

Annals of the rheumatic diseases·2026
Same author

Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.

Dermatology and therapy·2026
Same author

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

JAMA dermatology·2026
Same author

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Hidradenitis Suppurativa Patients Experience a Significant Musculoskeletal Symptom Burden: A Quality Improvement Initiative Using the IDEOM MSK-Q.

The Journal of clinical and aesthetic dermatology·2025
Same author

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.

Dermatology and therapy·2025
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

Psoriasis treatments have evolved from traditional immunomodulators like methotrexate to advanced biologics. While effective, both have side effects and require careful monitoring for optimal psoriasis management.

Area of Science:

  • Immunodermatology
  • Rheumatology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin disease often linked to joint complications.
  • Systemic therapies, including immunomodulators and biologics, are crucial for managing moderate-to-severe cases.

Purpose of the Study:

  • To review the evolution and efficacy of systemic therapies for psoriasis.
  • To discuss the benefits and drawbacks of pre-biological and biological agents.
  • To highlight current understanding and future directions in psoriasis treatment.

Main Methods:

  • Literature review of systemic immunomodulators and biologics for psoriasis.
  • Analysis of treatment efficacy, safety profiles, and monitoring requirements.
  • Examination of the impact of biologics on understanding psoriasis pathogenesis.

Related Experiment Videos

Main Results:

  • Methotrexate has been a long-standing treatment for moderate-to-severe psoriasis.
  • Biologics, such as tumor necrosis factor-blockers, offer advanced treatment options but have established safety concerns.
  • Biologics have significantly improved the understanding of psoriasis's underlying mechanisms.

Conclusions:

  • Systemic therapies have advanced psoriasis treatment, offering improved efficacy.
  • Careful patient monitoring and consideration of contraindications are essential for both traditional and biologic therapies.
  • Ongoing research into novel therapeutic targets promises further advancements in psoriasis care.